BR0312312A - Composto, formulação farmacêutica, uso de um composto, processo para a preparação de compostos, e, intermediários - Google Patents

Composto, formulação farmacêutica, uso de um composto, processo para a preparação de compostos, e, intermediários

Info

Publication number
BR0312312A
BR0312312A BR0312312-0A BR0312312A BR0312312A BR 0312312 A BR0312312 A BR 0312312A BR 0312312 A BR0312312 A BR 0312312A BR 0312312 A BR0312312 A BR 0312312A
Authority
BR
Brazil
Prior art keywords
group
optionally substituted
compound
fluorine
alkyl group
Prior art date
Application number
BR0312312-0A
Other languages
English (en)
Inventor
Asim Kumar Ray
Emma Margaretta Sigfridsson
Anna Stina Maria Linusson
Pernilla Marie Sandberg
Tord Inghardt
Anette Marie Svensson
Kay Brickmann
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0312312A publication Critical patent/BR0312312A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Quinoline Compounds (AREA)

Abstract

"COMPOSTO, FORMULAçãO FARMACêUTICA, USO DE UM COMPOSTO, PROCESSO PARA A PREPARAçãO DE COMPOSTOS, E, INTERMEDIáRIOS". A presente invenção fornece compostos de fórmula (I), em que R^ 1^ representa um grupo alcóxi C~ 1-4~ opcionalmente substituído com um ou mais flúor ou um grupo alquila C~ 1-4~ opcionalmente substituído com um ou mais flúor; n representa O ou 1; R^ 2^ representa um grupo alquila C~ 1-4~ opcionalmente substituído com um ou mais flúor ou um grupo alcóxi C~ 1-4~ opcionalmente substituído com um ou mais flúor; m representa O ou 1; R^ 3^ representa H ou um grupo alquila C~ 1-4~; L^ 1^ representa uma cadeia de alquileno (CH~ 2~)~ r~, em que r representa 2 ou 3, ou L^ 1^ representa um grupo cicloexila em que os dois nitrogênios que carregam R^ 3^ e R^ 4^, respectivamente, são ligados ao grupo cicloexila ou através das posições 1,3 ou 1,4 do grupo cicloexila, ou L^ 1^ representa um grupo ciclopentila em que os dois nitrogênios carregando R^ 3^ e R^ 4^, respectivamente, são ligados ao grupo ciclopentila através da posição 1,3 do grupo ciclopentila e, adicionalmente, quando R^ 5^ representa 9,10-metanoantracen-9(10H)-ila, o grupo -L^ 1^-N(R^ 4^)- junto representa um anel piperidila que é ligado a L^ 2^ através do nitrogênio da piperidinila, e a N-R^ 3^ através da posição 4 do anel piperidinila, com a condição de que, quando R^ 5^ representa 9,10-metanoantracen-9(10H)-ila então r é apenas 2; R^ 4^ representa H ou um grupo alquila C~ 1-4~ opcionalmente substituído com um ou mais do seguinte: um grupo arila ou um grupo heteroarila; L^ 2^ representa uma ligação ou uma cadeia de alquileno (CH~ 2~), em que s representa 1, 2 ou 3 em que a cadeia de alquileno é opcionalmente substituída com um ou mais do seguinte: um gmpo alquila C~ 1-4~, fenila ou heteroarila; W representa arila, um grupo heterocíclico ou um grupo cicloalquila C~ 3-8~, o qual é opcionalmente fundido a uma fenila ou a um grupo heteroarila, assim como seus isómeros ópticos ou racematos, bem como seus sais farmaceuticamente aceitáveis; com as condições, processos para preparar tais compostos, seu uso no tratamento de obesidade, distúrbios psiquiátricos, distúrbios cognitivos, distúrbios da memória, esquizofrenia, epilepsia, e condições relacionadas, e distúrbios neurológicos tais como demência, esclerose múltipla, Mal de Parkinson, coréia de Huntington, e Mal de Alzheimer, e distúrbios relacionados à dor, e a composições farmacêuticas contendo-os.
BR0312312-0A 2002-07-08 2003-07-04 Composto, formulação farmacêutica, uso de um composto, processo para a preparação de compostos, e, intermediários BR0312312A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0202134A SE0202134D0 (sv) 2002-07-08 2002-07-08 Therapeutic agents
PCT/GB2003/002884 WO2004004726A1 (en) 2002-07-08 2003-07-04 Mchir antagonists

Publications (1)

Publication Number Publication Date
BR0312312A true BR0312312A (pt) 2005-04-12

Family

ID=20288471

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0312312-0A BR0312312A (pt) 2002-07-08 2003-07-04 Composto, formulação farmacêutica, uso de um composto, processo para a preparação de compostos, e, intermediários

Country Status (19)

Country Link
US (1) US20060247439A1 (pt)
EP (1) EP1528924A1 (pt)
JP (1) JP2006501186A (pt)
CN (1) CN1665502A (pt)
AR (1) AR040476A1 (pt)
AU (1) AU2003281194A1 (pt)
BR (1) BR0312312A (pt)
CA (1) CA2491835A1 (pt)
CO (1) CO5680403A2 (pt)
IL (1) IL165841A0 (pt)
IS (1) IS7653A (pt)
MX (1) MXPA05000336A (pt)
NO (1) NO20045528L (pt)
PL (1) PL374674A1 (pt)
RU (1) RU2004138079A (pt)
SE (1) SE0202134D0 (pt)
TW (1) TW200412957A (pt)
WO (1) WO2004004726A1 (pt)
ZA (1) ZA200500030B (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1464335A3 (en) * 2003-03-31 2007-05-09 Taisho Pharmaceutical Co. Ltd. Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist
CN100451004C (zh) * 2003-03-31 2009-01-14 大正制药株式会社 嘧啶衍生物
GB0400193D0 (en) * 2004-01-07 2004-02-11 Astrazeneca Ab Therapeutic agents
JP2007517868A (ja) * 2004-01-07 2007-07-05 アストラゼネカ アクチボラグ 治療薬ｉ
RU2373197C2 (ru) * 2004-03-30 2009-11-20 Тайсо Фармасьютикал Ко., Лтд. Пиримидиновые производные, обладающие активностью в отношении мсн
WO2006015279A1 (en) * 2004-07-28 2006-02-09 Neurogen Corporation Heterocyclic diamine compounds as ligands of the melanin concentrating hormone receptor useful for the treatment of obesity, diabetes, eating and sexual disorders
WO2006035967A1 (en) * 2004-09-30 2006-04-06 Taisho Pharmaceutical Co., Ltd. Pyridine derivatives and their use as medicaments for treating diseases related to mch receptor
WO2006066174A1 (en) * 2004-12-17 2006-06-22 Eli Lilly And Company Thiazolopyridinone derivates as mch receptor antagonists
EP1978804B1 (en) * 2006-01-25 2014-07-30 Merck Sharp & Dohme Corp. Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
FR2902100A1 (fr) * 2006-06-13 2007-12-14 Sanofi Aventis Sa Molecules duales contenant un derive peroxydique, leur synthese et leurs applications en therapeutique
CN101516852B (zh) * 2006-09-28 2011-11-16 弗·哈夫曼-拉罗切有限公司 具有5-ht结合特性的喹啉衍生物
AU2009307884B2 (en) 2008-10-22 2014-07-31 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
SA110310332B1 (ar) 2009-05-01 2013-12-10 Astrazeneca Ab مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل )
SG181498A1 (en) 2009-12-04 2012-07-30 Sunovion Pharmaceuticals Inc Multicyclic compounds and methods of use thereof
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
AU2011275547B2 (en) 2010-07-06 2015-10-29 Astrazeneca Ab Therapeutic agents 976
US8796258B2 (en) 2011-02-25 2014-08-05 Merck Sharp & Dohme Corp. Cyclic azabenzimidazole derivatives useful as anti-diabetic agents
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
US20140045746A1 (en) 2012-08-02 2014-02-13 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP2016516004A (ja) 2013-02-22 2016-06-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病二環式化合物
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2018023072A2 (en) 2016-07-29 2018-02-01 Sunovion Pharmaceuticals, Inc. Compounds and compositions and uses thereof
EP3490607A4 (en) 2016-07-29 2020-04-08 Sunovion Pharmaceuticals Inc. COMPOUNDS AND COMPOSITIONS, AND USES THEREOF
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. ANTIDIABETIC HETEROCYCLIC COMPOUNDS
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. ANTIDIABETIC SPIROCHROMAN COMPOUNDS
ES2968227T3 (es) * 2016-12-23 2024-05-08 Aquinnah Pharmaceuticals Inc Compuestos, composiciones y procedimientos de uso
EP3582815A1 (en) 2017-02-16 2019-12-25 Sunovion Pharmaceuticals Inc. Methods of treating schizophrenia
JP7191085B2 (ja) 2017-08-02 2022-12-16 サノビオン ファーマシューティカルズ インク イソクロマン化合物およびその使用
US10815249B2 (en) 2018-02-16 2020-10-27 Sunovion Pharmaceuticals Inc. Salts, crystal forms, and production methods thereof
MX2021010880A (es) 2019-03-14 2022-01-18 Sunovion Pharmaceuticals Inc Sales de un compuesto de isocromanilo y formas cristalinas, procesos de preparacion, usos terapeuticos y composiciones farmaceuticas de las mismas.
CN115734785A (zh) 2020-04-14 2023-03-03 桑诺维恩药品公司 (S)-(4,5-二氢-7H-噻吩并[2,3-c]吡喃-7-基)-N-甲基甲胺用于治疗神经和精神方面的病症
US20240217951A1 (en) 2022-09-23 2024-07-04 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
US20240228469A1 (en) 2022-09-23 2024-07-11 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
US20240239767A1 (en) 2022-12-16 2024-07-18 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3020283A (en) * 1958-10-20 1962-02-06 Abbott Lab Bis-lepidines
JPH05507702A (ja) * 1990-05-30 1993-11-04 アメリカン・ホーム・プロダクツ・コーポレイション 置換アリールスルホンアミド類およびベンズアミド類
ZA974147B (en) * 1996-05-14 1997-11-14 Novo Nordisk As Somatostatin agonists and antagonists.
EP0973513A4 (en) * 1996-10-23 2003-03-19 Zymogenetics Inc COMPOSITIONS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH BONE DEFICIT
KR20010043131A (ko) * 1998-04-29 2001-05-25 피터 기딩스 Ｍｒｓ 억제제 및 살균제로서 사용되는 퀴놀론
US6489344B1 (en) * 1998-06-19 2002-12-03 Chiron Corporation Inhibitors of glycogen synthase kinase 3
ATE479429T1 (de) * 2000-04-28 2010-09-15 Takeda Pharmaceutical Antagonisten des melanin-konzentrierenden hormons
CA2433090A1 (en) * 2000-12-27 2002-07-04 Kyowa Hakko Kogyo Co., Ltd. Dipeptidyl peptidase iv inhibitor
EP1359915A4 (en) * 2001-01-26 2004-07-21 Smithkline Beecham UROTENSIN-II RECEPTOR ANTAGONISTS

Also Published As

Publication number Publication date
ZA200500030B (en) 2005-11-11
IL165841A0 (en) 2006-01-15
RU2004138079A (ru) 2005-08-10
AU2003281194A1 (en) 2004-01-23
IS7653A (is) 2005-01-19
PL374674A1 (en) 2005-10-31
TW200412957A (en) 2004-08-01
CA2491835A1 (en) 2004-01-15
WO2004004726A1 (en) 2004-01-15
MXPA05000336A (es) 2005-03-31
CO5680403A2 (es) 2006-09-29
NO20045528L (no) 2005-04-04
SE0202134D0 (sv) 2002-07-08
US20060247439A1 (en) 2006-11-02
EP1528924A1 (en) 2005-05-11
CN1665502A (zh) 2005-09-07
JP2006501186A (ja) 2006-01-12
AR040476A1 (es) 2005-04-06

Similar Documents

Publication Publication Date Title
BR0312312A (pt) Composto, formulação farmacêutica, uso de um composto, processo para a preparação de compostos, e, intermediários
AR038044A1 (es) Compuesto derivado de pirazina, composicion farmaceutica, su uso en la fabricacion de un medicamento, proceso para su preparacion y compuesto intermediario en dicho proceso.
EA200500342A1 (ru) Гетероциклические замещённые пиперазины для лечения шизофрении
PH12016502231A1 (en) Indolin-2-one or pyrrolo-pyridin-2-one derivatives
AR017182A1 (es) Compuestos de aminotiazol, inhibidores de las kinasas dependientes de ciclinas y las composiciones farmaceuticas que los contienen.
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR069510A1 (es) Arilo y heteroarilo imidazo[1,5-a]pirazinas fusionadas como inhibidores de la fosfodiesterasa 10
AR084457A1 (es) Derivados de biciclo[3,2,1]octilamida
AR038419A1 (es) Derivados de piridina y quinolina
AR038045A1 (es) Agentes terapeuticos
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
BR0212760A (pt) Compostos quìmicos
BRPI0110955B8 (pt) derivados de tropano composição farmacêutica, uso dos mesmos na fabricação de um medicamento bem como processo para a preparação dos mesmos.
BRPI0614168A2 (pt) Composto ou um sal, hidrato, solvato, isoforma, tautômero, isômero óptico farmaceuticamente aceitável ou uma combinação dos mesmos, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psquiátricos, uso de um composto, e, processo para a preparação de um composto
BRPI0308696B8 (pt) composto derivado de quinolina, seu processo de preparação, sua composição farmacêutica e seus usos
UY28374A1 (es) Agentes terapéuticos
AR077960A1 (es) Derivados de benzamida n-sustituidos como inhibidores del transportador de glicina 1 (glyt-1)
AR070885A1 (es) Compuestos de azaindol para el tratamiento de trastornos del sistema nervioso central
AR075160A1 (es) Derivados de aril y/o heteroaril piperidinas sustituidas, medicamentos que las contienen, proceso para prepararlas y uso de las mismas para el tratamiento de trastornos neurologicos y neuropsiquiatricos.
ES2676198T3 (es) Derivados amino-quinoxalina para el tratamiento de enfermedades neurodegenerativas
AR016644A1 (es) Compuestos de 2-aminopiridinas con sustituyentes alcoxi ramificados, composicion farmaceutica y uso para la manufactura de medicamentos
BR0308765A (pt) Compostos (4,2-dissubstituìdo-tiazol-5-il)amina como inibidores de pde7
AR044579A1 (es) Antagonistas de nmda/ nr2b nonaril - heterociclicos n- sustituidos
ES2094742T3 (es) Aminocarbonilcarbamatos relacionados con fisostigmina, un procedimiento para su preparacion y su uso como medicamentos.
EA200501148A1 (ru) Пиридилоксиметильные и бензизоксазольные азабициклические производные

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A, 5A,6A E 7A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2064 DE 27/07/2010.